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Abstract
For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as
topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are
expensive and sufficient numbers are not available. Therefore, a small animal model that facilitates rapid evaluation of
potential candidates for their preliminary efficacy is urgently needed in the microbicide field. We previously demonstrated
that RAG-hu humanized mouse model permits HIV-1 mucosal transmission via both vaginal and rectal routes and that oral
pre-exposure chemo-prophylactic strategies could be tested in this system. Here in these proof-of-concept studies, we
extended this system for topical microbicide testing using HIV-1 as the challenge virus. Maraviroc, a clinically approved
CCR5 inhibitor drug for HIV treatment, was formulated as a microbicide gel at 5 mM concentration in 2.2% hydroxyl ethyl
cellulose. Female RAG-hu mice were challenged vaginally with HIV-1 an hour after intravaginal application of the maraviroc
gel. Our results showed that maraviroc gel treated mice were fully protected against vaginal HIV-1 challenge in contrast to
placebo gel treated mice which all became infected. These findings highlight the utility of the humanized mouse models for
microbicide testing and, together with the recent data from macaque studies, suggest that maraviroc is a promising
candidate for future microbicide clinical trials in the field.
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Introduction
More than a million women contract HIV infection annually
through unprotected sex due to the lack of a simple self
implementable preventive measure [1]. In this regard, an ideal
vaginally applied anti-HIV microbicide will have a great impact in
reducingthenumberofnewcases[2,3].Suchamicrobicidewillalso
empower women to protect themselves from HIV infected non-
compliant partners. While a number of non-specific compounds
proved to be ineffective in the early clinical trials, the recent
significant success achieved with the RT inhibitor tenofovir
demonstrated the merits of exploiting viral target specific com-
pounds as potential HIV microbicides [3,4]. There are currently
more than 30 clinically licensed anti-HIV drugs and many more
new ones are in the pipeline [5]. A number of these anti-HIV drugs
show considerable promise as topically applied microbicides.
However, for these to reach the clinical trial stage, it is necessary
to conduct in vivo efficacy and safety testing in animal models.
Macaque models have long been used for HIV microbicide
testing and are considered the gold standard because of many
similarities with human genital tract anatomy and physiology [6].
Tenofovir is an example of a microbicide candidate that was
initially evaluated in the monkey model [4]. However, due to the
high cost and limited supply it is not feasible to solely rely on
using macaques to conduct large scale initial screening of
numerous compounds to identify a select number of new
candidates. Another limitation with the macaque model is that
it does not employ HIV-1 for challenge studies thus somewhat
limiting its predictive value with regard to drugs that are
specifically designed to be effective against HIV-1, but not SIV
or SHIV viruses. Moreover, it is not possible to evaluate
candidate microbicides against drug resistant and genetically
divergent field HIV-1 viral strains. Based on these constraints,
many potentially promising candidates will not be able to
progress beyond in vitro testing. Therefore, a small animal
model that can overcome some of the above limitations will
greatly help speed-up the process of microbicide screening.
Humanized mouse models harboring HIV-1 susceptible
human target cells can potentially be exploited for this purpose
[7,8]. The SCID-hu-PBL humanized mouse model prepared by
passive transfer of human PBLs was utilized in this context in
early microbicide evaluations [9,10,11]. However, the infection
rate was found to be variable and therefore not fully reliable for
microbicide testing due to low levels of repopulation by human
cells in the vaginal mucosa [12]. To improve human cell
engraftment, more recent humanized mouse models incorpo-
rated transplantation of human hematopoietic stem cells
(CD34
+ cells) into immunodeficient mice with much compro-
mised innate immunity [7,8,13]. Mouse strains such as NOD/
SCIDcc
2/2 and Rag2
2/2cc
2/2 allowed superior human
cell engraftment levels resulting in a more robust multi-
lineage human hematopoiesis and engraftment of primary and
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mouse model, is created by an improvement of the conventional
SCID-hu mouse model which involves transplantation of thymic
and liver tissues under the kidney capsule followed by injection
with autologous human CD34
+ cells [14]. Both these human-
ized mouse models have been shown to support intestinal,
vaginal and rectal mucosal tissue engraftment by human HIV-1
target cells such as CD4+ Tc e l l sa n dm a c r o p h a g e s[ 1 5 , 1 6 , 1 7 ] .
A number of groups including ours have demonstrated the
utility of these humanized mice as improved models for HIV-1
infection and CD4 T cell depletion [18,19,20,21,22,23].
Importantly, these models also permit HIV-1 mucosal trans-
mission via both vaginal and rectal routes [15,24] thus making it
possible to experimentally evaluate novel prevention strategies
of HIV-1 sexual transmission. Indeed, in a pre-exposure
prophylactic approach (PrEP), systemic administration of TDF
(tenofovir) and FTC (emtricitabine) was found to prevent HIV-1
vaginal transmission using the BLT mouse model [24,25]. In a
similar approach, using the RAG-hu humanized mouse model,
we recently showed that oral administration of two clinically
approved new generation compounds namely, the integrase
inhibitor raltegravir and a CCR5 inhibitor maraviroc confers
protection against HIV-1 vaginal challenge [26].
However, successful testing of topically administered microbi-
cide compounds for prevention of HIV-1 sexual transmission has
thus far not been reported using either of these mouse models. The
current list of potential anti-HIV microbicide candidates is
dominated by post-entry viral inhibitors such as tenofovir and
emtricitabine [4,27]. As pointed out above, tenofovir has already
been tested in human clinical trials and showed partial protection
in the field [4]. For an ideal microbicide, it is even more desirable
to prevent viral entry which is the first step in viral infection. In
this regard, the clinically approved CCR5 inhibitor maraviroc
holds great promise and is being considered as a potential anti-
HIV microbicide, and indeed recent macaque studies demon-
strated that it can protect against a SHIV virus vaginal challenge
[28]. Here we show that vaginal application of a gel formulation of
maraviroc confers full protection against HIV-1 vaginal challenge
in RAG-hu mice thus also validating a new small animal model for
future HIV microbicide testing.
Materials and Methods
Preparation of humanized Rag2
2/2cc
2/2 mice (RAG-hu
mice)
Humanized BALB/c-Rag2
2/2cc
2/2 and BALB/c-Rag1
2/2
cc
2/2 (RAG-hu) mice were generated by transplanting with
human fetal liver-derived CD34
+ hematopoietic progenitor cells as
we previously described [15,20]. Mice were maintained at the
Colorado State University Painter Animal Center. These studies
have been reviewed and specifically approved by the CSU
Institutional Animal Care and Use Committee (Protocol 09-
085A). Briefly, newborn mice were conditioned by irradiating at
350 rads and then injected intrahepatically with 0.521610
6
human CD34
+ cells. Mice were screened for human cell
engraftment at 10–12 weeks post-reconstitution. Peripheral blood
was collected by tail bleed and red blood cells were lysed by using
the Whole Blood Erythrocyte Lysing Kit (R&D Systems,
Minneapolis, MN). The white blood cell fraction was stained with
antibodies against the human pan-leukocyte marker CD45
(Caltag) and FACS analyzed to determine the levels of human
cell engraftment as we previously described [20]. Female mice
prepared with different donor CD34+ cells with over 60%
engraftment (Table 1) were randomly picked for vaginal infections
as detailed below. Mice used in these experiments were not
monitored for estrus.
Table 1. Summary of human cell engraftment levels in humanized mice*.
Uninfected Control Placebo
Mouse Gender %Engraftment Mouse Gender %Engraftment
889 Female 75.9 924 Female 63.7
890 Female 81.5 925 Female 66.4
926 Female 67.0
J848 Female 92.5
J849 Female 82.5
J850 Female 93.8
Maraviroc Treated
Mouse Gender %Engraftment
912 Female 85.5
913 Female 88.8
J830 Female 94.0
J831 Female 80.0
J832 Female 90.6
J833 Female 94.3
J834 Female 83.2
*Peripheral blood was collected from human CD34 cell reconstituted RAG-hu mice (BALB/c-Rag2
2/2cc
2/2 or BALB/c-Rag1
2/2cc
2/2, the prefix J is indicative of RAG1) at
10–12 weeks post engraftment. White blood cell fraction was stained with human CD45 FITC conjugated antibody and analyzed by FACS to confirm human cell
engraftment prior to maraviroc or placebo gel treatments and vaginal HIV-1 challenges.
doi:10.1371/journal.pone.0020209.t001
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by vaginal route
Female RAG-hu mice were topically administered with either a
placebo gel (6 mice) or maraviroc gel (7 mice) an hour before viral
challenge. Clinical formulation of Maraviroc in a 150 mg tablet
form ((Selzentry, Pfizer Labs) was ground and freshly dissolved in
phosphate-buffered saline, sterile-filtered and adjusted to a final
concentration of 4 mg/mL (7.8 mM). A 3.4% gel preparation of
hydroxyl-ethyl cellulose (HEC) was added to the dissolved drug to
achieve a final concentration of 5 mM maraviroc in 2.2% HEC
gel. A 25 ml volume of the gel formulation was carefully applied in
to the vaginal vault of mice. Control mice received 2.2% HEC
placebo gel. An hour post-gel application, mice were challenged
vaginally with HIV-1 BaL (3000 TCID) in a 25 ml volume. The
gel and viral inoculums were applied by using the bulbous end
(1.25 mm in diameter) of a newborn mouse straight 24 gauge
gavage needle (purchased from VWR, made by POPPER, N.Y) to
assure no abrasions and tearing. Mice were anesthetized by
isoflurane inhalation for 7–10 minutes during the procedures.
Anesthetized mice were held in an inverted position for four
minutes post-inoculation to allow virus to adsorb and to prevent
immediate discharge of virus as described previously [15,26].
Animals were observed daily and blood samples collected on a
weekly basis to assess plasma viremia and CD4 T cell counts.
Measurement of viral loads
Viral infection and viral loads were assessed by Q-RT-PCR.
RNA was extracted from 25–50 ul of EDTA-treated plasma using
the QIAamp Viral RNA kit (Qiagen, Valencia, CA). Q-PCR was
performed by using a primer set specific for the HIV-1 LTR
sequence and a corresponding LTR specific probe as described
previously [15,29]. To detect integrated form of the virus, cellular
DNA was extracted using QIAmp DNA Blood kit (Qiagen,
Valencia, CA) and subjected to q-RT-PCR by the iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA) to determine proviral
loads.
Flow cytometry
Mice were monitored to measure the levels of CD4 T cells in
the peripheral blood. Whole blood was collected and red blood
cells lysed as reported previously [20,29]. Peripheral blood cells
were stained for hCD3-PE and hCD4-PECy5 (Caltag) markers
and analyzed using a Coulter EPICS XL-MCL FACS anal-
yzer (Beckman Coulter, Fullerton, CA). CD4
+ T cell levels
were calculated as a ratio of the entire CD3 population
(CD4
+CD3
+:CD4
2CD3
+). All mice were analyzed prior to
infection to establish baseline CD4
+ T cell ratios.
Results
Vaginal application of maraviroc gel protects humanized
mice against HIV-1 vaginal challenge
We have previously established that RAG-hu humanize mice
permit mucosal HIV-1 infection by both vaginal and rectal routes
[15] and have recently shown that oral administration of anti-
retrovirals, maraviroc and raltegravir protect these mice against
HIIV-1 vaginal challenge [26]. Here we evaluated maraviroc as a
topically applied microbicide gel to prevent HIV-1 sexual
transmission. To assess efficacy, maraviroc was administered
vaginally one hour prior to vaginal viral challenge to mimic a
coital dependant context. Mouse plasma and blood cellular
fractions were analyzed by Q-PCR weekly and bi-weekly
respectively to ascertain the HIV-1 infection status. Our results
showed that the placebo-gel administered and HIV-1 challenged
mice started becoming virus positive by the third week with all of
them infected by the 5th week post challenge (Fig. 1). Persistent
viremia in plasma and proviral loads in the cellular fractions were
observed throughout the evaluation period with viral loads
reaching up to 10
6 RNA copies/ml (Fig. 2A) and proviral DNA
copies at 10
5 DNA copies/ml (Fig. 2B). In contrast, none of the
maraviroc treated mice became infected (Fig. 1). No evidence of
infection was seen throughout the 16 week observation period as
evaluated by either RNA or DNA PCR (Fig. 2A and B). These
data taken together suggest that vaginal administration of
maraviroc fully protects mice against HIV-1 vaginal challenge.
CD4 T cell loss in placebo-gel administered mice
compared to maraviroc-gel protected mice
A typical finding in HIV-1 infected humanized mice is a gradual
CD4 T cell loss as seen in the human. Although the PCR data
demonstrated no viral infection in maraviroc treated mice, we
further evaluated the virus challenged mice for any evidence of
CD T cell loss to confirm lack of any HIV associated pathology
[20,29]. Peripheral blood was collected bi-weekly and subjected to
FACS analysis. To establish a baseline, CD4 T cell levels were
measured prior to viral challenge for each of the experimental
mice and later compared to the levels determined post-viral
challenge. While there was a clear pattern of CD4 T cell decline in
placebo-gel treated and viral challenged mice, their levels were
stable in mice receiving maraviroc gel (Fig. 3) further validating
the prevention of HIV-1 transmission in these mice.
Discussion
With the dearth of a protective vaccine in the immediate future,
deployment of an effective vaginally applied anti-HIV microbicide
would greatly aid in stemming the HIV epidemic [3]. To reach
this goal, new viral specific anti-HIV compounds need to be tested
as topical microbicides using a suitable in vivo system. In these
proof-of-concept studies, we have shown that a topical microbicide
gel formulation of the CCR5 inhibitor drug maraviroc fully
protects humanized mice from HIV-1 challenge via vaginal route
Figure 1. Vaginal application of maraviroc gel protects
humanized mice against vaginal HIV-1 challenge. RAG-hu mice
were challenged by vaginal route one hour after vaginal administration
of maraviroc as described in Methods. Blood was collected weekly from
infected mice and the status of HIV-1 infection was determined by
Q-RT-PCR. Kaplan-Meier plots of time course of appearance of viremia
in drug treated versus non-treated virus challenged mice.
doi:10.1371/journal.pone.0020209.g001
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recent study had shown the efficacy of maraviroc in preventing
vaginal infection in rhesus macaques by a CCR-5 using SHIV-
162P3 hybrid virus [28], our present results demonstrated the
efficacy of the drug against HIV-1 in a human target cell context
in humanized mice. In addition to supporting the results of the
macaque studies, our findings extended them to the primary
culprit HIV-1 itself against which the drug was originally designed
and intended thus providing a more direct evidence.
Due to its capacity as a CCR5 antagonist, the small molecular
drug maraviroc inhibits the binding of native physiological ligands
of CCR5, namely CCL3 (also known as MIP-1a), CCL4 (MIP1-b)
and CCL5 (RANTES) [30]. It is shown to have sustained antiviral
activity due its long lasting physical and functional occupancy of
CCR5 receptor. It has potent effect against all R5 tropic viruses
representing various viral clades, and is also shown to be effective
against a wide array of drug resistant viruses [31]. A major
advantage with drugs such as maraviroc compared to RT
inhibitors is that the first step in infection, viral entry, is inhibited
thus providing an up-front protection.
To simulate the use of the microbicide in coital context,
maraviroc gel was applied vaginally one hour before HIV-1 R5
viral challenge. The 5 mM maraviroc concentration we used is
close to the dose (6 mM) found to be most protective in monkey
studies using a similar 2.2% HEC carrier gel formulation [28].
However, in contrast to the above studies, it was not necessary to
subject the humanized mice to progesterone hormonal (Depo-
Provera) treatment to induce vaginal thinning to facilitate
efficient vaginal infection. While all the placebo-gel treated,
vaginally HIV-1 challenged mice (n=6) became infected within
five weeks, none of the maraviroc treated mice (n=7) showed any
evidence of infection by either RT-PCR or DNA-PCR throu-
ghout the sixteen week observation period. Thus protection
conferred by maraviroc gel against HIV-1 vaginal challenge is
highly significant (p value 0.0006, Fisher’s exact test). In addition
to viral detection, we also looked for any evidence of helper CD4
T cell loss which is a typical feature of HIV-1 infection. A trend
of declining CD4 T cell counts was noticed as expected in
placebo-gel treated mice in contrast to those receiving maraviroc
(Fig. 3). These data taken together showed that maraviroc fully
protected mice from vaginal HIV-1 challenge.
The above promising data together with those using SHIV viral
challenges in macaques strongly suggest maraviroc as an attractive
candidate for further development as a topically administered anti-
HIV microbicide. Since it is not yet widely used in other parts of
the world where HIV prevalence is high, it will have a good
resistance barrier. However it should be noted that maraviroc will
not protect against X4 tropic and/or dual tropic viruses. With
Figure 2. RNA and DNA viral loads in mice administered with maraviroc. RAG-hu mice were challenged by vaginal route after an hour after
vaginal application of maraviroc as described in Methods. Blood was collected weekly. Viral RNA was extracted from the plasma fraction and DNA was
extracted from the cellular fraction. Viral RNA and DNA loads were determined by Q-PCR as described in methods. The dotted lines represent limits of
PCR detection. A. RNA viral loads B. DNA viral loads.
doi:10.1371/journal.pone.0020209.g002
Figure 3. CD4 T cell decline in non-treated vaginally challenged mice in contrast to mice protected with maraviroc gel. Levels of CD4
T cells were monitored on a weekly by FACS basis to determine their decline in treated versus non-treated mice. Baseline values for each of the mice
were established prior to infection as described in Methods.
doi:10.1371/journal.pone.0020209.g003
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the HIV microbicides arena is currently focused on only a few
HIV-1 specific compounds such as RT inhibitors tenofovir and
emtricitabine [27]. While the partial protection afforded by
tenofovir gel is encouraging, it is by no means adequate to be
deployed as a sole candidate to protect the large at-risk population
[4]. Therefore, it is necessary that many new compounds be tested
to identify candidates with a good chance for success. Further-
more, it is generally understood that a single drug would not be
adequate to achieve broad efficacy and therefore a combinations
of drugs need to be tested [2,32,33]. Such testing in a primate
model will be cost-prohibitive. In this regard, humanized mice are
likely to fill the gap for deriving preliminary data and in laying the
ground work for subsequent macaque studies. Since HIV-1 itself
can be used as a challenge virus, various drug resistant mutants
that exist in the field can also be evaluated against different
combinations of potential promising compounds.
While both RAG-hu and BLT mouse models have been
successfully used to demonstrate the efficacy of systemically
administered anti-HIV drugs for pre-exposure prophylaxis
[25,26], our present results have extended the utility of RAG-hu
mouse model for topical microbicide testing as well. Both these
models are likely to play an important role in the development of
new PrEP strategies that encompass systemic and/or topical use of
anti-HIV drugs. In this context, the RAG-hu mouse model offers
some practical advantages over BLT mice. First, its preparation is
not technically intensive as no surgical procedure is required to
implant thymic and liver tissues under the kidney capsule as is
necessary to generate BLT mice. Second, RAG-hu mice have a
longer life span compared to BLT mice (NOD/SCID mice used
to prepare BLT mice experience a high incidence of lymph-
omas), thus permitting long-term studies. For example, effect of
microbicides on the mucosal membranes during long-term
application can be evaluated. Third, for any large scale testing,
an adequate cohort of humanized mice is needed. In this regard,
greater numbers of RAG-hu mice can be generated per human
tissue donor compared to BLT mice. For example, depending on
available tissue quantity and CD34+ cell yield, 30–60 mice can be
generated.
In summary, we have shown that a maraviroc gel can prevent
HIV-1 vaginal transmission. These data also helped validate the
utility of humanized mice for testing topical microbicides. Now it is
possible to conduct large scale in vivo preliminary screenings of a
large number of potential microbicide candidates in a cost effective
manner. In addition, a number of important questions regarding
protection against cell associated virus, influence of estrus and low
dose repeated viral challenges on the microbicide efficacy can be
evaluated in the future.
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